RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 190 filers reported holding RECURSION PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 1.13 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $134,342 | -60.3% | 17,561 | -61.2% | 0.01% | -67.7% |
Q2 2023 | $338,346 | -2.9% | 45,294 | -13.3% | 0.03% | -62.7% |
Q1 2023 | $348,621 | +6520.2% | 52,267 | +7552.6% | 0.08% | +8200.0% |
Q4 2022 | $5,266 | -24.8% | 683 | -18.8% | 0.00% | 0.0% |
Q2 2022 | $7,000 | – | 841 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Obvious Management Services, L.L.C. | 3,985,087 | $42,401,000 | 100.00% |
Two Sigma Ventures, LP | 903,400 | $9,612,000 | 100.00% |
DCVC Opportunity Fund II GP, LLC | 3,951,141 | $42,040,000 | 54.37% |
Data Collective IV GP, LLC | 5,941,120 | $63,214,000 | 49.97% |
MIC Capital Management UK LLP | 8,451,758 | $89,927,000 | 16.21% |
MV Management XI, L.L.C. | 1,971,908 | $20,981,000 | 15.20% |
ArchPoint Investors | 1,116,126 | $11,876,000 | 4.85% |
HARVARD MANAGEMENT CO INC | 1,509,254 | $16,058,000 | 2.00% |
PLATINUM INVESTMENT MANAGEMENT LTD | 2,251,971 | $23,961,000 | 1.00% |
Duquesne Family Office | 1,385,950 | $14,747,000 | 0.84% |